



an Open Access Journal by MDPI

Impact of Nanobiotechnology (Nanomedicine) on the Future of Medicine: The Road toward Precision Medicine

Guest Editor:

Prof. Dr. Shaker A. Mousa

1. Retired, The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, NY 12144, USA

2. Vascular Vision Pharmaceuticals Co., Rensselaer Polytechnic Park, Troy, NY 12180, USA

Deadline for manuscript submissions:

closed (31 December 2019)

Message from the Guest Editor

Dear Colleagues,

The scope of this Special Issue is to cover recent progress in nanotechnology/biotechnology as it relates to nanomedicine, targeted delivery of medicines and biomedicines, diagnostics. A key aim is to bring latest advances of various nanomedicine approaches for the detection and treatment of various types of organ specific diseases, vascular targeting, vaccine development, and the overall impact of Nanomedicine on advancing precision medicines. Additionally, this issue aims to cover nano nutraceuticals, nano cosmetics using single or combination of various bioactive compounds derived from natural products and impact on diseases prevention.



mdpi.com/si/11390

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI